PL3768674T3 - Pochodne aminopirymidyny jako inhibitory ctps1 - Google Patents
Pochodne aminopirymidyny jako inhibitory ctps1Info
- Publication number
- PL3768674T3 PL3768674T3 PL19713022.2T PL19713022T PL3768674T3 PL 3768674 T3 PL3768674 T3 PL 3768674T3 PL 19713022 T PL19713022 T PL 19713022T PL 3768674 T3 PL3768674 T3 PL 3768674T3
- Authority
- PL
- Poland
- Prior art keywords
- aminopyrimidine derivatives
- ctps1 inhibitors
- ctps1
- inhibitors
- aminopyrimidine
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163772.9A EP3543232A1 (en) | 2018-03-23 | 2018-03-23 | Aminopyrimidine derivatives as ctps1 inhibitors |
| EP18175823.6A EP3578551A1 (en) | 2018-06-04 | 2018-06-04 | Sulfonamide derivatives |
| EP18202136 | 2018-10-23 | ||
| PCT/EP2018/086617 WO2019179652A1 (en) | 2018-03-23 | 2018-12-21 | Aminopyrimidine derivatives as ctps1 inhibitors |
| PCT/EP2019/057320 WO2019180244A1 (en) | 2018-03-23 | 2019-03-22 | Aminopyrimidine derivatives as ctps1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3768674T3 true PL3768674T3 (pl) | 2024-04-29 |
Family
ID=64949297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19713022.2T PL3768674T3 (pl) | 2018-03-23 | 2019-03-22 | Pochodne aminopirymidyny jako inhibitory ctps1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210024507A1 (pl) |
| EP (1) | EP3768674B1 (pl) |
| JP (2) | JP7428692B2 (pl) |
| KR (1) | KR20200135463A (pl) |
| CN (1) | CN111868051B (pl) |
| AU (1) | AU2018413791B2 (pl) |
| BR (1) | BR112020018701A2 (pl) |
| CA (1) | CA3093050A1 (pl) |
| DK (1) | DK3768674T3 (pl) |
| EA (1) | EA202092263A1 (pl) |
| ES (1) | ES2974445T3 (pl) |
| FI (1) | FI3768674T3 (pl) |
| HR (1) | HRP20240375T8 (pl) |
| HU (1) | HUE066693T2 (pl) |
| IL (1) | IL277455B2 (pl) |
| LT (1) | LT3768674T (pl) |
| MX (1) | MX2020009887A (pl) |
| PH (1) | PH12020500655A1 (pl) |
| PL (1) | PL3768674T3 (pl) |
| SG (1) | SG11202103238XA (pl) |
| SI (1) | SI3768674T1 (pl) |
| WO (1) | WO2019179652A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11505547B2 (en) | 2017-11-30 | 2022-11-22 | Step Pharma S.A.S. | Compounds |
| WO2019106156A1 (en) | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
| MX2021004659A (es) | 2018-10-23 | 2021-05-28 | Step Pharma S A S | Derivados de aminopirimidina/pirazina como inhibidores de ctps1. |
| EP3980410A1 (en) | 2019-06-04 | 2022-04-13 | Step Pharma S.A.S. | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases |
| US20220324837A1 (en) * | 2019-06-04 | 2022-10-13 | Step Pharma S.A.S. | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
| WO2021053403A1 (en) | 2019-09-20 | 2021-03-25 | Step Pharma S.A.S. | Sulfonamide inhibitors as ctps1 inhibitors |
| WO2021053402A2 (en) | 2019-09-20 | 2021-03-25 | Step Pharma S.A.S. | Compounds |
| TW202233612A (zh) * | 2020-10-23 | 2022-09-01 | 美商林伯士科羅索公司 | Ctps1抑制劑及其用途 |
| WO2023166078A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor |
| WO2023166077A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
| WO2023166076A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combinations of ctps1 and bcl2 inhibitors for cancer |
| WO2024133721A1 (en) | 2022-12-21 | 2024-06-27 | Step Pharma S.A.S. | Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer |
| WO2024133730A1 (en) | 2022-12-21 | 2024-06-27 | Step Pharma S.A.S. | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer |
| CN118359588A (zh) * | 2023-01-19 | 2024-07-19 | 杭州英创医药科技有限公司 | 作为ctps1抑制剂的化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR056871A1 (es) * | 2005-10-04 | 2007-10-31 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2011506445A (ja) * | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| KR101097312B1 (ko) * | 2009-08-10 | 2011-12-23 | 삼성모바일디스플레이주식회사 | 유기 발광 소자 |
| CN105473136A (zh) * | 2013-04-18 | 2016-04-06 | 国家健康与医学研究院 | 用于在有此需要的受试者中抑制淋巴细胞增殖的方法和药物组合物 |
| GB201322333D0 (en) * | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
| WO2016016370A1 (en) * | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists |
-
2018
- 2018-12-21 WO PCT/EP2018/086617 patent/WO2019179652A1/en active Application Filing
- 2018-12-21 MX MX2020009887A patent/MX2020009887A/es unknown
- 2018-12-21 CN CN201880091502.6A patent/CN111868051B/zh active Active
- 2018-12-21 IL IL277455A patent/IL277455B2/en unknown
- 2018-12-21 CA CA3093050A patent/CA3093050A1/en active Pending
- 2018-12-21 JP JP2021500333A patent/JP7428692B2/ja active Active
- 2018-12-21 AU AU2018413791A patent/AU2018413791B2/en active Active
- 2018-12-21 KR KR1020207030329A patent/KR20200135463A/ko not_active Application Discontinuation
-
2019
- 2019-03-22 HU HUE19713022A patent/HUE066693T2/hu unknown
- 2019-03-22 HR HRP20240375TT patent/HRP20240375T8/hr unknown
- 2019-03-22 LT LTEPPCT/EP2019/057320T patent/LT3768674T/lt unknown
- 2019-03-22 SG SG11202103238XA patent/SG11202103238XA/en unknown
- 2019-03-22 SI SI201930725T patent/SI3768674T1/sl unknown
- 2019-03-22 PL PL19713022.2T patent/PL3768674T3/pl unknown
- 2019-03-22 FI FIEP19713022.2T patent/FI3768674T3/fi active
- 2019-03-22 EA EA202092263A patent/EA202092263A1/ru unknown
- 2019-03-22 EP EP19713022.2A patent/EP3768674B1/en active Active
- 2019-03-22 BR BR112020018701-1A patent/BR112020018701A2/pt unknown
- 2019-03-22 US US16/982,641 patent/US20210024507A1/en not_active Abandoned
- 2019-03-22 DK DK19713022.2T patent/DK3768674T3/da active
- 2019-03-22 ES ES19713022T patent/ES2974445T3/es active Active
-
2020
- 2020-08-27 PH PH12020500655A patent/PH12020500655A1/en unknown
-
2023
- 2023-10-19 JP JP2023180542A patent/JP2024020222A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019179652A1 (en) | 2019-09-26 |
| HUE066693T2 (hu) | 2024-08-28 |
| EP3768674A1 (en) | 2021-01-27 |
| JP2024020222A (ja) | 2024-02-14 |
| FI3768674T3 (fi) | 2024-04-02 |
| PH12020500655A1 (en) | 2021-06-21 |
| CN111868051B (zh) | 2024-04-09 |
| DK3768674T3 (da) | 2024-02-19 |
| IL277455B1 (en) | 2024-01-01 |
| JP2021518436A (ja) | 2021-08-02 |
| US20210024507A1 (en) | 2021-01-28 |
| JP7428692B2 (ja) | 2024-02-06 |
| LT3768674T (lt) | 2024-04-25 |
| SG11202103238XA (en) | 2021-04-29 |
| AU2018413791B2 (en) | 2023-05-18 |
| MX2020009887A (es) | 2020-10-12 |
| HRP20240375T8 (hr) | 2024-06-21 |
| AU2018413791A1 (en) | 2020-09-17 |
| CN111868051A (zh) | 2020-10-30 |
| CA3093050A1 (en) | 2019-09-26 |
| KR20200135463A (ko) | 2020-12-02 |
| EP3768674B1 (en) | 2024-01-03 |
| SI3768674T1 (sl) | 2024-05-31 |
| HRP20240375T1 (hr) | 2024-06-07 |
| EA202092263A1 (ru) | 2021-01-15 |
| IL277455A (en) | 2020-11-30 |
| IL277455B2 (en) | 2024-05-01 |
| ES2974445T3 (es) | 2024-06-27 |
| BR112020018701A2 (pt) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277455A (en) | History of aminopyrimidines as CTPS1 inhibitors | |
| IL282386A (en) | Aminopyrimidine/pyrazine history as CTPS1 inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL275207A (en) | An oxyfluoropiperidine derivative as a kinase inhibitor | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| AU2017904208A0 (en) | Novel kinase inhibitors i |